SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Reuther T, Schuster T, Mende U, Kubler A 2003 Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients: A report of a thirty year retrospective review. Int J Oral Maxillofac Surg 32: 289295.
  • 2
    Wahl MJ 2006 Osteoradionecrosis Prevention Myths. Int J Radiat Oncol Biol Phys 64: 661669.
  • 3
    Carter GD, Goss AN 2003 Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48: 268.
  • 4
    Migliorati CA 2003 Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21: 42534254.
  • 5
    Marx RE 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61: 11151117.
  • 6
    Ruggiero SL, Mehotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the Jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62: 527534.
  • 7
    Durie BG, Katz M, Crowley J 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: 99100.
  • 8
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukos V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23: 85808587.
  • 9
    Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T 2006 Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24: 945952.
  • 10
    Van Poznak CH, Estilo CL, Sauter NP, Hudis C, Tunick S, Huryn JM, Halpern J 2004 Osteonecrosis of the jaw in patients with metastatic breast cancer. Breast Cancer Res Treat 88 (Suppl 1): S131.
  • 11
    Woo S-B, Hellstein JW, Kalmar JR 2006 Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753761.
  • 12
    Tosi P, Zamagni E, Cangini D, Tachetti P, DiRaimondo F, Catalano L, DÁrco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolinin M, Brioli A, Tura S, Baccarani M, Cavo M 2006 Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 108: 39513952.
  • 13
    Kraj M, Ryszard P, Stanislaw M, Owczarska K 2006 The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates. Acta Pol Pharm 63: 450452.
  • 14
    Sanna G, Zampino MG, Pelosi G, Nole F, Goldhirsh A 2005 Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 16: 12071208.
  • 15
    Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrili F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G 2007 Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 48: 5664.
  • 16
    Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E 2006 Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134: 620623.
  • 17
    Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A 2006 Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91: 968971.
  • 18
    Rodan GA, Fleisch HA 1996 Bisphosphonates: Mechanism of action. J Clin Invest 97: 26922696.
  • 19
    Fleisch H 1998 Bisphosphonates: Mechanism of action. Endocr Rev 19: 80100.
  • 20
    Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 17851791.
  • 21
    Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ 1999 Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial-Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846854.
  • 22
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y 2001 Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer and osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7: 377387.
  • 23
    Rosen LS, Gordon D, Tchekmedyan S, Yanagihara R, Hirsh V, Krakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ 2003 Zoledronic acid versus placebo in the treatment of skeletal metastases I patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 31503157.
  • 24
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 14581468.
  • 25
    Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K 2006 Bisphosphonate-induced hypocalcemia: Report of 3 cases and review of literature. Endocr Pract 12: 4853.
  • 26
    Guarneri V, Donati S, Nicolini M, Giovanelli S, D'Amico R, Conte PF 2005 Renal Safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10: 842848.
  • 27
    Green JR, Muller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9: 745751.
  • 28
    Bilezikian JP 2006 Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med 355: 22782281.
  • 29
    Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V 2006 Practical guidelines for the prevention, diagnosis and treatment of osteronecrosis of the jaw in patients with cancer. J Oncol Pract 2: 714.
  • 30
    Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M 2007 International Society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43: 852858.
  • 31
    Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA 2007 Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients–May 2006. Crit Rev Oncol Hematol 62: 148152.
  • 32
    Bone HG, Hosking D, Devogeloer JD, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 11891199.
  • 33
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR FLEX Research Group 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296: 29272938.
  • 34
    Odvina CV, Zerweck JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 12941301.